USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Dec 31, 2021 (est) | Sep 30, 2021 | - | $-0.42 | $-0.38 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Dec 31, 2021 (est) | Sep 30, 2021 | - | $0.00 | $0.00 |
Aditx Therapeutics, Inc's next estimated earnings date (based on same quarter last year's date) is Dec 31, 2021 for the fiscal quarter ending Sep 30, 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $0.56 | $0.56 | $0.56 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $0.22 | $0.22 | $0.22 |
| Dec 2022 | 0 | $0.00 | $0.00 | $0.00 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $0.56 | $0.56 | $0.56 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $0.22 | $0.22 | $0.22 |
| Dec 2022 | 0 / 0 | $0.90 | $0.90 | $0.90 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $5.50M | $5.50M | $5.50M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $11.00M | $11.00M | $11.00M |
| Dec 2022 | 1 | $42.42M | $42.42M | $42.42M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $-0.05 | $-0.42 | -740.00% |
| Jun 30, 2021 | Mar 2021 | $-0.21 | $-0.42 | -102.00% |
| Mar 31, 2021 | Dec 2020 | $-0.29 | $-0.46 | -59.07% |
| Dec 31, 2020 | Sep 2020 | - | $-0.38 | - |
| Sep 30, 2020 | Jun 2020 | - | $-0.37 | - |
| Jun 30, 2020 | Mar 2020 | - | $-0.14 | - |
| Mar 31, 2020 | Dec 2019 | - | $-0.30 | - |
| Dec 31, 2019 | Sep 2019 | - | $-0.26 | - |
| Sep 30, 2019 | Jun 2019 | - | $-0.28 | - |
| Jun 30, 2019 | Mar 2019 | - | $-0.67 | - |
| Mar 31, 2019 | Dec 2018 | - | $-0.32 | - |
| Dec 31, 2018 | Sep 2018 | - | $-0.14 | - |
| Sep 30, 2018 | Jun 2018 | - | $-0.39 | - |
| Jun 30, 2018 | Mar 2018 | - | $-0.52 | - |
| Mar 31, 2018 | Dec 2017 | - | $-0.52 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 31, 2021 | Dec 2020 | $-0.73 | $-1.35 | - |
| Mar 31, 2020 | Dec 2019 | - | $-1.51 | - |
| Mar 31, 2019 | Dec 2018 | - | $-1.37 | - |
| Mar 31, 2018 | Dec 2017 | - | $-0.52 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $1.00M | $0.00 | - |
| Jun 30, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 31, 2021 | Dec 2020 | - | $0.00 | - |
| Dec 31, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Sep 30, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| Jun 30, 2020 | Mar 2020 | - | $0.00 | - |
| Mar 31, 2020 | Dec 2019 | - | $0.00 | - |
| Dec 31, 2019 | Sep 2019 | - | $0.00 | - |
| Sep 30, 2019 | Jun 2019 | - | $0.00 | - |
| Jun 30, 2019 | Mar 2019 | - | - | - |
| Mar 31, 2019 | Dec 2018 | - | - | - |
| Dec 31, 2018 | Sep 2018 | - | - | - |
| Sep 30, 2018 | Jun 2018 | - | - | - |
| Jun 30, 2018 | Mar 2018 | - | - | - |
| Mar 31, 2018 | Dec 2017 | - | - | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 31, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 31, 2020 | Dec 2019 | - | $0.00 | - |
| Mar 31, 2019 | Dec 2018 | - | $0.00 | - |
| Mar 31, 2018 | Dec 2017 | - | - | - |
ADTX's next estimated earnings date (based on same quarter last year's report date) is Dec 31, 2021 for the fiscal quarter ending Sep 30, 2021.
Aditx Therapeutics, Inc's previous earnings date was Aug 12, 2021 for its fiscal quarter ended Jun 30, 2021.
ADTX's earnings per share (EPS) was $-0.42, missing the consensus analysts forecast of $-0.05 by -740.00%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -0.99%, and lower than the same period a year before (Jun 2020) by 13.85%.
Revenues were $0.00.
The company reported a net income of $-6.18M.Free cash flow for the quarter was $-5.24M , compared to $-4.54M last quarter and $-154.67K a year before.
ADTX ended the quarter with $8.61M in total debt, an increase of 51.97% compared to the previous quarter, and an increase of 923.83% compared to the same quarter a year before.
Aditx Therapeutics, Inc's previous annual earnings date was Mar 31, 2021 for its fiscal year ended Dec 31, 2020.
ADTX's earnings per share (EPS) was $-1.35, missing the consensus analysts forecast of $-0.73 by 84.34% , and higher than the previous year's EPS (Dec 2019) by -10.82%.
Revenues were $0.00.
The company reported a net income of $-9.15M.
Aditx Therapeutics, Inc reported a free cash flow of $-7.39M for its fiscal year, compared to $-464.35K a year ago.
The company ended the fiscal year with $1.84M in total debt, an increase of 1009.22% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.